Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection
- PMID: 19084927
- PMCID: PMC2776871
- DOI: 10.3748/wjg.14.7149
Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection
Abstract
Chemokines produced in the liver during hepatitis C virus (HCV) infection induce migration of activated T cells from the periphery to infected parenchyma. The milieu of chemokines secreted by infected hepatocytes is predominantly associated with the T-helper cell/Tc1 T cell (Th1/Tc1) response. These chemokines consist of CCL3 (macrophage inflammatory protein-1 alpha; MIP-1 alpha), CCL4 (MIP-1 beta), CCL5 (regulated on activation normal T cell expressed and secreted; RANTES), CXCL10 (interferon-gamma-inducible protein-10; IP-10), CXCL11 (interferon-inducible T-cell alpha chemoattractant; I-TAC), and CXCL9 (monokine induced by interferon gamma; Mig) and they recruit T cells expressing either CCR5 or CXCR3 chemokine receptors. Intrahepatic and peripheral blood levels of these chemokines are increased during chronic hepatitis C. The interaction between chemokines and their receptors is essential in recruiting HCV-specific T cells to control the infection. When the adaptive immune response fails in this task, non-specific T cells without the capacity to control the infection are also recruited to the liver, and these are ultimately responsible for the persistent hepatic damage. The modulation of chemokine receptor expression and chemokine secretion could be a viral escape mechanism to avoid specific T cell migration to the liver during the early phase of infection, and to maintain liver viability during the chronic phase, by impairing non-specific T cell migration. Some chemokines and their receptors correlate with liver damage, and CXCL10 (IP-10) and CXCR3 levels have shown a clinical utility as predictors of treatment response outcome. The regulation of chemokines and their receptors could be a future potential therapeutic target to decrease liver inflammation and to increase specific T cell migration to the infected liver.
Figures







Similar articles
-
The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection.J Viral Hepat. 2007 Oct;14(10):675-87. doi: 10.1111/j.1365-2893.2006.00838.x. J Viral Hepat. 2007. PMID: 17875002 Review.
-
Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C.Hepatology. 2008 Nov;48(5):1440-50. doi: 10.1002/hep.22500. Hepatology. 2008. PMID: 18798334 Free PMC article.
-
The role of CCR5/CXCR3 expressing CD8+ cells in liver damage and viral control during persistent hepatitis C virus infection.J Hepatol. 2007 Nov;47(5):632-41. doi: 10.1016/j.jhep.2007.04.009. Epub 2007 May 24. J Hepatol. 2007. PMID: 17560677
-
Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver.J Immunol. 1999 Dec 1;163(11):6236-43. J Immunol. 1999. PMID: 10570316
-
Hepatocellular carcinoma and CXCR3 chemokines: a narrative review.Clin Ter. 2017 Jan-Feb;168(1):e37-e41. doi: 10.7417/CT.2017.1980. Clin Ter. 2017. PMID: 28240761 Review.
Cited by
-
Cytokine expression patterns in hospitalized children with Bordetella pertussis, Rhinovirus or co-infection.Sci Rep. 2021 May 26;11(1):10948. doi: 10.1038/s41598-021-89538-0. Sci Rep. 2021. PMID: 34040002 Free PMC article.
-
CD44 participates in IP-10 induction in cells in which hepatitis C virus RNA is replicating, through an interaction with Toll-like receptor 2 and hyaluronan.J Virol. 2012 Jun;86(11):6159-70. doi: 10.1128/JVI.06872-11. Epub 2012 Apr 4. J Virol. 2012. PMID: 22491449 Free PMC article.
-
Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients.World J Gastroenterol. 2011 Dec 21;17(47):5184-90. doi: 10.3748/wjg.v17.i47.5184. World J Gastroenterol. 2011. PMID: 22215943 Free PMC article. Clinical Trial.
-
Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy.World J Gastroenterol. 2018 Dec 21;24(47):5297-5311. doi: 10.3748/wjg.v24.i47.5297. World J Gastroenterol. 2018. PMID: 30598575 Free PMC article. Review.
-
CXCL10 Chemokine: A Critical Player in RNA and DNA Viral Infections.Viruses. 2022 Nov 3;14(11):2445. doi: 10.3390/v14112445. Viruses. 2022. PMID: 36366543 Free PMC article. Review.
References
-
- Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41–52. - PubMed
-
- Afdhal NH. The natural history of hepatitis C. Semin Liver Dis. 2004;24 Suppl 2:3–8. - PubMed
-
- Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965. - PubMed
-
- Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982. - PubMed
-
- Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol. 2006;1:23–61. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials